Ketone precursors and methods therefor
The development of diester compounds that enzymatically convert to (R)-3-hydroxybutyrate in vivo addresses the limitations of existing (R)-3-hydroxybutyrate delivery methods, offering a stable, palatable, and metabolically effective solution for ketone body production.
Patent Information
- Application Number
- JP2024526981
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-04
- Filing Date
- 2022-11-03
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2042-11-03
AI Technical Summary
Existing compositions and methods for delivering (R)-3-hydroxybutyrate suffer from issues such as high cost, undesirable side effects, low solubility, chemical instability, and insufficient palatability, as well as the production of undesired stereoisomers during hydrolysis.
Development of diester compounds that undergo enzymatic hydrolysis in vivo to produce (R)-3-hydroxybutyrate, utilizing metabolically relevant dicarboxylic acids like succinic acid, malic acid, and alpha-ketoglutaric acid, which are formulated for oral administration and have high solubility and stability, and are substrates for lipases and esterases.
The diester compounds effectively generate (R)-3-hydroxybutyrate in vivo, providing a cost-effective, palatable, and stable source of ketone bodies with enhanced metabolic benefits, including improved energy production and therapeutic effects.
Smart Images

Figure 2024542150000001_ABST
Abstract
Description
[Technical field]
[0001] This application claims priority to co-pending U.S. Provisional Patent Application No. 63 / 275,858, filed November 4, 2022, and incorporated herein by reference.
[0002] The field of the invention relates to compositions and methods for delivering precursors of (R)-3-hydroxybutyrate to mammals, particularly compounds formulated as precursors formed from metabolically related (di)carboxylic acids and 1,3-butanediol. [Background technology]
[0003] The Background Discussion includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0004] All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. In the event that a definition or use of a term in an incorporated reference is inconsistent with or contrary to the definition of that term provided herein, the definition of that term provided herein shall apply and the definition of that term in the reference shall not apply.
[0005] Nutritional or therapeutic ketosis is a physiological state of elevated blood ketone body levels (typically above 0.5 mmol / L) resulting from a ketogenic diet, caloric restriction, therapeutic fasting, and / or supplementation with ketogenic precursors. Ketone bodies are alternative energy substrates for both peripheral tissues and the central nervous system. The two most abundant and physiologically important ketone bodies are acetoacetate and (R)-3-hydroxybutyrate (also called beta-hydroxybutyrate), while a third ketone body, acetone, is produced as a by-product of exhaled air by the lungs. The body produces ketone bodies during nutritional or therapeutic ketosis, and ketone body metabolism is associated with anticonvulsant effects, enhanced brain metabolism, neuroprotection, muscle sparing properties, and improved cognitive and physical performance. Science-based improvements in cellular metabolic efficiency managed by ketone supplementation may have beneficial effects on the physical, cognitive health, psychological health, and resilience of soldiers, as well as long-term impacts on health related to common avoidable diseases such as obesity, neurodegenerative diseases, diabetes, and cancer, reduce fatigue, may provide anti-aging effects, reduce aging of skin and other tissues and organs, and may have regulatory effects on immunity and inflammation.
[0006] During periods of carbohydrate deprivation, the body uses energy obtained from fat metabolism. During fat metabolism, fat is converted to acetoacetate and 3-hydroxybutyrate, known as ketone bodies, and large amounts of these substances accumulate in the blood. This state is known as ketosis and occurs commonly during starvation. Once blood ketone body concentrations are elevated to levels seen during prolonged starvation, they provide the brain's primary source of energy. In addition to being a unique high-energy metabolic substrate, (R)-3-hydroxybutyrate has diverse potential therapeutic applications. For example, it may increase cardiac and cerebral metabolic efficiency and reduce the effects of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease. Additionally, (R)-3-hydroxybutyrate may serve as an alternative physiological energy source.
[0007] Although (R)-3-hydroxybutyrate can be administered directly, such direct administration is not practical. For example, (R)-3-hydroxybutyrate is relatively expensive, has a bitter taste, and can lead to undesirable side effects due to significant acidosis following rapid absorption from the gastrointestinal tract. Furthermore, when hydroxybutyrate is provided as a salt, it is likely to result in unacceptable sodium levels when higher doses of hydroxybutyrate are consumed. In an attempt to avoid the intake of large amounts of sodium or other cations, various (R)-3-hydroxybutyrate derivatives have been tested to ultimately deliver (R)-3-hydroxybutyrate as a metabolite. However, the synthesis of all or nearly all of these derivatives requires expensive precursors and / or has undesirable S-isomer by-products. Among other examples, known (R)-3-hydroxybutyrate derivatives include 3-hydroxybutyl-(R)-3-hydroxybutyrate (US2019 / 0014798) and mixed (R)-3-hydroxybutyrate oligomers (US2018 / 0195096). In yet a further example, monoesters can be formed between (R)-3-hydroxybutyrate and 1,3-butanediol, as discussed in US2020 / 0113220. However, such monoesters still require stereochemically pure reagents, increasing product costs and potential issues with enantiomeric purity.
[0008] In yet another approach utilizing 1,3-butanediol as a metabolic precursor to (R)-3-hydroxybutyrate, the exogenous ketone diester bishexanoyl-(R)-1,3-butanediol (BH-BD) is used as a dietary source for ketone precursor delivery. The diester is formed from one molecule of (R)-1,3-butanediol and two molecules of hexanoic acid to generate BH-BD. After ingestion, the BH-BD diester is hydrolyzed and the resulting (R)-1,3-butanediol is converted to (R)-3-hydroxybutyrate in the liver in a non-classical step, while the remaining hexanoic acid molecule is converted to (R)-3-hydroxybutyrate in the liver in a classical (beta-oxidative) step. Further exemplary diester compounds are described in US2019 / 0248730. Similarly, US 2021 / 0186914 teaches an R,S-1,3-butanediol acetoacetate diester used to treat cachexia. The diester is formed from one molecule of 1,3-butanediol and two molecules of acetoacetate.
[0009] At least some of such compounds and compositions tend to be less expensive to manufacture and / or do not provide excessive amounts of sodium or other cations when ingested in significant amounts, but still have various disadvantages.Among other things, they may be poorly palatable, and at least some of these compounds have undesirably low solubility in aqueous media.Moreover, many of these compounds have low chemical stability, and non-enzymatic hydrolysis of these compounds produces racemic 3-hydroxybutyrate, one stereoisomeric form of which is not significantly metabolized to energy. Summary of the Invention
[0010] Thus, although various compositions and methods for (R)-3-hydroxybutyrate or its precursors are known in the art, all or nearly all of them suffer from some shortcomings.Therefore, there remains a need for improved compounds, compositions and methods for (R)-3-hydroxybutyrate and its precursors.
[0011] The present subject matter is directed to various compounds, compositions and methods for providing 3-hydroxybutyrate, particularly (R)-3-hydroxybutyrate, to a mammal by compounds that deliver a precursor from which (R)-3-hydroxybutyrate is produced in vivo and also produce a second metabolically related compound.
[0012] In a preferred embodiment, following oral administration of a contemplated compound, enzymatic hydrolysis of the contemplated compound proceeds to produce (R)-3-hydroxybutyrate in vivo to form (R)-1,3-butanediol, which is further enzymatically oxidized to (R)-3-hydroxybutyrate. Enzymatic hydrolysis also produces dicarboxylic acids, which in particularly preferred embodiments are metabolically related compounds, such as the dicarboxylic acids of the citric acid cycle. Advantageously, the contemplated compounds have significant solubility in aqueous media, desirable palatability and chemical stability, and can serve as substrates for a variety of stereoselective hydrolases (e.g., lipases, esterases).
[0013] In one aspect of the subject matter of the present invention, the inventors provide a compound of formula I [ka]
[0014] (wherein X is a linear alkyl group optionally containing at least one double bond and optionally substituted with a substituent selected from the group consisting of a methyl group, a hydroxyl group, an amino group, and a keto group, and * denotes a chiral carbon atom). In one embodiment, the present invention contemplates a nutritional composition comprising a nutritionally acceptable carrier in combination with a diester compound having a structure according to the invention, and formulated for oral administration.
[0015] In some embodiments, X is (CH2). nand n is an integer between 1 and 10. In a further embodiment, the linear alkyl group is substituted with at least one keto group. In yet a further embodiment, the linear alkyl group is substituted with at least one hydroxyl group. In yet a further embodiment, the linear alkyl group is substituted with at least one amino group. In a further embodiment, the linear alkyl group is substituted with at least one methyl group. In a still further embodiment, the linear alkyl group has at least one double bond.
[0016] It is also contemplated that at least one of the chiral carbon atoms has an (R)-configuration, and / or that the diester compound is a substrate for lipase or esterase. Thus, it is contemplated that the diester compound produces (R)-1,3-butanediol and / or produces metabolically relevant dicarboxylic acids after hydrolysis by lipase or esterase. For example, metabolically relevant dicarboxylic acids include intermediates in the tricarboxylic acid (TCA) cycle, intermediates or substrates of beta-oxidation, intermediates or substrates of glycolysis, and / or intermediates or substrates of gluconeogenesis. Thus, contemplated metabolically relevant dicarboxylic acids include, inter alia, succinic acid, malic acid, fumaric acid, and alpha-ketoglutaric acid.
[0017] As a result, the inventors have discovered that the diester compound is of formula II, III, IV or V [ka] It is contemplated that the structure may be as follows:
[0018] If desired, contemplated compositions may further include (R)-1,3-butanediol, (R)-3-hydroxybutyrate, and / or dicarboxylic acid. As will be appreciated, contemplated compositions may be formulated as liquids, such as liquid concentrates, ready-to-drink beverages, or gels, or may be formulated as solids, such as bulk powders, tablets or capsules, lozenges, dissolving films, or snack bars.
[0019] In some embodiments, the compositions may be formulated into solid dosage units to provide between 20 mg and 1,000 mg of the diester compound per dosage unit to a consumer who ingests a dosage unit of the composition, hi other embodiments, the compositions may be formulated into liquid dosage units to provide between 2 g and 30 g of the diester compound per dosage unit to a consumer who ingests a dosage unit of the composition.
[0020] Thus, in a further aspect of the subject matter of the present invention, the inventors also contemplate a method of increasing (R)-3-hydroxybutyrate in a mammal, comprising orally administering to the mammal a nutritional composition as presented herein. Most typically, the diester compound is then enzymatically converted in the mammal to produce (R)-1,3-butanediol and a dicarboxylic acid, and then the (R)-1,3-butanediol is further enzymatically converted in the mammal to produce (R)-3-hydroxybutyrate.
[0021] For example, the composition may be administered in a solid dosage unit to provide the mammal with between 20 mg and 1,000 mg, or between 100 mg and 2,000 mg, of the diester compound, typically in the form of one or more tablets or capsules, or in a liquid dosage unit to provide the mammal with between 2 g and 30 g of the diester compound, typically in the form of a gel or a ready-to-drink product (e.g., an energy drink or flavored beverage).
[0022] In yet another aspect of the inventive subject matter, the inventors also contemplate a method of producing a nutritional composition, comprising combining a diester compound with a nutritionally acceptable carrier, thereby producing a nutritional composition. Most typically, the diester compound is represented by formula I [ka]
[0023] (wherein X is a linear alkyl group optionally containing at least one double bond and optionally substituted with a substituent selected from the group consisting of a methyl group, a hydroxyl group, an amino group, and a keto group, and * denotes a chiral carbon atom). and in a further step, the nutritional composition is formulated for oral administration.
[0024] In some embodiments, the diester compounds may be produced by direct esterification of metabolically relevant dicarboxylic acids and 1,3-butanediol, particularly (R)-1,3-butanediol. Among other options, the metabolically relevant dicarboxylic acids may be intermediates in the tricarboxylic acid (TCA) cycle, intermediates or substrates of beta-oxidation, intermediates or substrates of glycolysis, or intermediates or substrates of gluconeogenesis. Thus, suitable metabolically relevant dicarboxylic acids include succinic acid, malic acid, fumaric acid, and alpha-ketoglutaric acid. Preferably, but not necessarily, the direct esterification comprises enzymatic esterification.
[0025] In other embodiments, the diester compound may be produced by transesterification of a dicarboxylic acid diester intermediate and 1,3-butanediol, particularly (R)-1,3-butanediol. For example, a suitable dicarboxylic acid diester intermediate may be a diester of ethanol and a metabolically relevant dicarboxylic acid, which may be an intermediate in the tricarboxylic acid (TCA) cycle, an intermediate or substrate of beta-oxidation, an intermediate or substrate of glycolysis, or an intermediate or substrate of gluconeogenesis. Thus, suitable metabolically relevant dicarboxylic acids include succinate, malate, fumarate, and alpha-ketoglutarate. Preferably, but not necessarily, the transesterification involves enzymatic transesterification.
[0026] In further contemplated embodiments of such methods, X is (CH) n where n is an integer between 1 and 10. Accordingly, suitable diester compounds are of formula II, III, IV or V [ka] It may have a structure according to TIFF2024542150000006.tif30142.
[0027] Various objects, features, aspects and advantages of the present subject matter will become more apparent from the following detailed description of preferred embodiments, taken in conjunction with the accompanying drawings, in which like numerals represent like elements throughout. [Brief description of the drawings]
[0028] [Figure 1] 1 is a schematic diagram showing the metabolic pathway for the enzymatic degradation of a first exemplary compound in accordance with the present subject matter.
[0029] [Diagram 2] 1 is a schematic diagram showing the metabolic pathway for the enzymatic degradation of a second exemplary compound in accordance with the present subject matter.
[0030] [Diagram 3] 1 is a schematic diagram showing the metabolic pathway for the enzymatic degradation of a third exemplary compound in accordance with the present subject matter.
[0031] [Figure 4] 1 is a schematic diagram showing the metabolic pathway for the enzymatic degradation of a fourth exemplary compound in accordance with the present subject matter. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] The present inventors have discovered various compounds, compositions and methods that provide (R)-3-hydroxybutyrate and metabolically related compounds to individuals. Most preferably, the contemplated compounds are prepared in a conceptually simple and efficient manner, have high solubility in aqueous media, desirable palatability, and allow for the selective production of (R)-3-hydroxybutyrate in vivo. In a further advantageous embodiment, it should also be understood that the contemplated compounds deliver 2 moles of (R)-1,3-butanediol per mole of metabolically related compounds, which can then be further enzymatically oxidized to (R)-3-hydroxybutyrate.
[0033] In this context, it should be understood that among the various contemplated metabolically related compounds, particularly preferred metabolically related compounds include various dicarboxylic acids that are intermediates or substrates in the tricarboxylic acid (TCA) cycle, intermediates or substrates of beta-oxidation, intermediates or substrates of glycolysis, or intermediates or substrates of gluconeogenesis. Thus, exemplary preferred metabolically related compounds include succinic acid, malic acid, fumaric acid, and alpha-ketoglutaric acid. However, various other substituted and unsubstituted dicarboxylic acids and tricarboxylic acids are also considered suitable for use herein and are discussed in more detail below. In addition, it should be noted that, although diesters with (R)-1,3-butanediol are generally preferred, mixed diesters formed with (S)-1,3-butanediol and (R)-1,3-butanediol are also considered suitable for use herein.
[0034] Therefore, from a different perspective, the present inventors have found that a compound of formula I: [ka] (wherein X is a linear alkyl group optionally containing at least one double bond and optionally substituted with a substituent selected from the group consisting of methyl, methylene, hydroxyl, amino and keto groups, and * denotes a chiral carbon atom).
[0023] A variety of compositions containing compounds having the structure of the formula: Preferably, but not necessarily, * independently represents the (R)-configuration.
[0035] In the most typical example, X is (CH2) n where n is an integer between 1 and 10, and as can be seen from Tables 1-3 below, contemplated compounds include keto, methyl, methylene and amino groups (particularly, X is (CH2) n and n is an integer greater than 3) and / or may be further substituted with a hydroxyl group. In less typical cases, the compounds according to the inventive subject matter may also have one or more double bonds.
[0036] As can be easily understood, the contemplated compounds are preferably the normal reaction products of one molecule of metabolically related (di / tri)carboxylic acid and two molecules of (R)-1,3-butanediol. Therefore, from a different perspective, the contemplated compounds are hydrolyzable (preferably enzymatically) into one molecule of metabolically related (di / tri)carboxylic acid and two molecules of (R)-1,3-butanediol. Among other suitable options, the contemplated diester or triester compounds are typically cleavable by lipase or esterase. Thus, in most cases, the contemplated diester or triester compounds produce (R)-1,3-butanediol as a reaction product together with the corresponding metabolically related (di / tri)carboxylic acid.
[0037] For example, suitable linear saturated dicarboxylic acids are shown in Table 1, while exemplary substituted dicarboxylic acids are shown in Table 2. Exemplary unsaturated dicarboxylic acids are shown in Table 3, and contemplated tricarboxylic acids are shown in Table 4. [Table 1] [Table 2] [Table 3] [Table 4]
[0038] In some embodiments, the metabolically relevant carboxylic acids can be further characterized as di- or tricarboxylic acids that are part of the metabolism (anabolism and / or catabolism) of a microorganism or eukaryote in which the di- or tricarboxylic acid is an intermediate or substrate. Thus, contemplated compounds can be used to supplement an individual with both (R)-1,3-butanediol (to produce (R)-3-hydroxybutyrate in vivo) and metabolically relevant di- or tricarboxylic acids.
[0039] Thus, exemplary compounds within the scope of compounds having a structure according to Formula I are represented by Formulas II-V: [ka] It is a compound having the structure
[0040] In a further aspect of the subject matter of the present invention, it should be recognized that the synthesis of the contemplated compounds is conceptually simple and effective, and can be carried out in high yields under stereochemically controlled conditions. In general, metabolically related di- or tri-carboxylic acids are reacted with 1,3-butanediol (preferably (R)-1,3-butanediol), thereby forming the corresponding di- or triester compounds. Although numerous esterification modes are considered suitable for use herein, particularly preferred methods include enzyme-mediated direct esterification or enzyme-mediated transesterification.
[0041] For example, di- or tricarboxylic acids in direct esterification can be reacted with excess (R)-1,3-butanediol in the presence of a catalyst (typically a suitable enzyme or an organic or inorganic acid or salt). Technically, direct esterification can be carried out in both homogeneous and heterogeneous modes (e.g., by applying immobilized enzymes or acidic resins), batch or flow modes. The resulting water production from the esterification reaction can be continuously removed, e.g., by adsorption / chemisorption using hygroscopic salts or molecular sieves, or can be distilled off as a constituent of an azeotrope.
[0042] Transesterification typically requires a diethyl ester of a di- or tricarboxylic acid and an excess of (R)-1,3-butanediol and a suitable catalyst, typically a suitable enzyme or an organic or inorganic acid or salt. Transesterification can be carried out in both homogeneous and heterogeneous manner (e.g. by applying immobilized enzymes or acidic resins), in batch or flow mode. In contrast to direct esterification, transesterification produces ethanol, which (always) needs to be removed. As ethanol is more volatile than water, it can be distilled off under reduced pressure as a component of an azeotrope or on its own.
[0043] For example, suitable enzymes include commercially available lipases, such as those from Candida antartica, Candida cylinderacea, Mucor meihei, Pseudomonas cepacia, and Pseudomonas fluorescens, and suitable methods for enzymatic esterification can be found in Zaccone F et al., An Alternative Enzymatic Route to the Ergogenic Ketone Body Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate. Catalysts. 2021; 11(1):140, which is incorporated herein by reference in its entirety. In an exemplary exemplary embodiment, the enzyme / substrate mixture is maintained under reduced pressure at a temperature of about 30°C for a predetermined length of time to allow for the desired degree of enzymatic esterification. Further exemplary reactions for direct esterification and transesterification are presented below in the section entitled "Examples." The desired reaction products can then be isolated using methods well known in the art, suitable methods including distillation, membrane filtration, adsorption onto solid phases, and various chromatographic methods.
[0044] During the formation of the compound, 1,3-butanediol may be present in excess. In certain embodiments, 1,3-butanediol is present in excess at a molar ratio of 1,3-butanediol to metabolically relevant carboxylic acid of 2:1 to 20:1, optionally 4:1 to 10:1, or optionally about 5:1. The method may further comprise isolating the excess 1,3-butanediol from the mixture. The step of isolating the excess 1,3-butanediol may comprise vacuum distillation. The excess 1,3-butanediol may be recovered (e.g., 80% recovery) and diverted to another reaction or recycled to the same reaction. Alternatively, it is not necessary to remove excess or even residual 1,3-butanediol from the reaction, since 1,3-butanediol is nutritionally acceptable and may serve as a precursor to 3-hydroxybutyrate. In these and other embodiments, it should be recognized that (R)-1,3-butanediol is inexpensive, food-friendly, and natural. More importantly, the use of (R)-1,3-butanediol as a precursor leads to the formation of 3-hydroxybutyrate in the (R) configuration, which is the metabolically relevant enantiomer of 3-hydroxybutyrate, by enzymatic oxidation in the liver. In the same manner, the contemplated compounds can be concentrated, isolated, or purified by ion exchange or other types of chromatography to remove undesired impurities. For example, unesterified or partially esterified di / tricarboxylic acids with free acidic moieties can be immobilized on ion exchange resins, while the desired compounds do not bind to such resins.
[0045] It should be understood that after synthesis and optional purification of the diester or triester contemplated herein, the compounds according to the present subject matter can be used as nutritional agents to provide or supplement or supplement (R)-3-hydroxybutyrate and / or metabolically related compounds. As a result, compositions comprising the compounds according to the present subject matter are also provided. Most preferably, such compositions are for oral administration. However, other routes of administration, particularly systemic administration by injection or infusion, are also considered suitable. Non-limiting examples of preferred compositions include dietary supplements and pharmaceutical compositions. Dietary supplements may be in liquid or solid form containing the contemplated compounds, and typically also include a nutritionally acceptable carrier. As will be readily understood, the nutritionally acceptable carrier may also function to impart certain textures or physical parameters, and may aid in the solidification (or adsorption to a solid phase) of the compound if it is liquid at room temperature.
[0046] For example, when dietary supplement is in solid form, the composition can be formulated as snack bar, lozenge, bulk powder, dissolving film, tablet or capsule, or can be coated on cereal products or included in baked goods.On the other hand, when supplement is in liquid form, the composition can be formulated as ready-to-drink beverage, liquid concentrate for mixing with aqueous solution, gel, carbonated drink, infusion drink (for example, as coffee or tea), juice, energy drink, sports drink or flavored water.In addition, pharmaceutical composition containing compound can be typically formulated as liquid for oral administration or injection.
[0047] Preferably, but not necessarily, the contemplated composition is formulated for oral consumption in dosage units to assist users in consuming the composition in desired amounts.For example, when the composition is formulated into solid dosage units, such dosage units may be designed to provide between 20mg and 1,000mg of diester compound to the consumer who ingests a dosage unit of the composition.On the other hand, the composition may also be formulated into liquid dosage units that provide a larger amount of diester compound per dosage unit, such as between 2g and 30g, to the consumer who ingests a dosage unit of the composition.
[0048] While nutritional and pharmaceutical compositions for human use are specifically contemplated, it should be understood that the compounds and formulations may also be employed for veterinary use, such as in animal feed for household companion animals ("pets") or in animal feed for livestock. In further contemplated aspects, the compounds may also be provided as bulk products (e.g., in amounts of 100 g or more, 1,000 g or more, or 10 kg or more) for use in the manufacture of nutritional or pharmaceutical products.
[0049] Depending on the particular formulation, the contemplated compounds may contain at least 5 mg, more typically at least 50 mg, and most typically at least 100 mg of the compounds presented herein, depending on the serving size or dosage unit. Thus, from another perspective, depending on the particular type of final product (e.g., energy or flavored drinks or fortified solid foods or capsules / tablets), the contemplated compounds may be present in the composition at a concentration of between 0.0001% and 0.01% by weight, or between 0.01% and 0.1% by weight, or between 0.1% and 1.0% by weight, or between 1.0% and 10% by weight, or between 10% and 99% by weight. Suitable dosage amounts for the contemplated compounds are generally between 100 mg and 50 g, and even higher amounts. Most commonly, the dosage unit is given at once (e.g., by oral capsule, beverage consumption, etc.), although it is noted that the dosage unit may also be given over two or more administrations.
[0050] Thus, from another perspective, the contemplated compounds may be used to deliver metabolically related di- or tri-carboxylic acids to a mammal together with (R)-3-hydroxybutyrate to support or generate a state of ketosis in the mammal and / or counteract (e.g., age-related) depletion of (R)-3-hydroxybutyrate. Notably, the presence of metabolically related di- or tri-carboxylic acids may enhance, and in some cases synergistically enhance, the physiological action of (R)-3-hydroxybutyrate. It should also be understood that the compounds contemplated herein are metabolized continuously in various physiological compartments, and thus the availability and activity of reaction products produced in vivo may have different effects in different physiological compartments (e.g., effects on microbiota, intestinal tissue, cellular metabolism and / or energy production, etc.).
[0051] Exemplary in vivo transformations are shown diagrammatically in Figures 1-4 for selected compounds. More specifically, exemplary compound 1 in Figure 1 may be hydrolyzed in vivo by esterases found in one or more physiological compartments to form succinic acid and (R)-1,3-butanediol. Exemplary compound 2 in Figure 2 may be hydrolyzed in vivo by esterases found in one or more physiological compartments to form malic acid and (R)-1,3-butanediol, while exemplary compound 3 in Figure 3 may be hydrolyzed in vivo by esterases found in one or more physiological compartments to form fumaric acid and (R)-1,3-butanediol. Exemplary compound 4 in Figure 4 may be hydrolyzed in vivo by esterases found in one or more physiological compartments to form ketoglutaric acid and (R)-1,3-butanediol. The resulting (R)-1,3-butanediol may then be metabolized in the liver to form (R)-3-hydroxybutyrate.
[0052] For example, lipase and / or esterase in saliva and intestinal fluid may release mainly di- or tri-carboxylic acids, while (R)-1,3-butanediol may be metabolized in the liver to form (R)-3-hydroxybutyrate. Thus, different reaction products may be available at different times and different locations in an organism that ingests the compounds presented herein. Notably, hydrolysis of diester or triester compounds may lead to the formation of 2 or 3 molecules of (R)-1,3-butanediol for each diester or triester molecule at different times. Thus, this initial and subsequent delayed release of (R)-1,3-butanediol may lead to the initial and delayed formation of (R)-3-hydroxybutyrate.
[0053] In various embodiments, the composition is substantially free of carbohydrates. The phrase "substantially free" as used herein with respect to carbohydrates means that carbohydrates may be present in an amount of 1% by weight or less, optionally 0.1% by weight or less, optionally 0.01% by weight or less, or 0.001% by weight or less based on the total weight of the composition. The term "carbohydrates" as used herein refers to sugars, starches, and fibers that can be metabolized to glucose.
[0054] It is also contemplated that the compositions may include additional ketone precursors or supplements for use in combination with the compounds. These additional ketone precursors or supplements may include medium chain fatty acids, inorganic salts, acetoacetate, other ketone esters, and other compounds that may cause elevated blood ketone levels.
[0055] Non-limiting examples and sources of medium chain fatty acids or esters thereof include medium chain triglycerides, including coconut oil, coconut milk powder, fractionated coconut oil, palm oil, palm kernel oil, caprylic acid, isolated medium chain fatty acids such as isolated hexanoic acid, isolated octanoic acid, isolated decanoic acid, purified or natural forms of medium chain triglycerides such as coconut oil and ester derivatives of medium chain fatty acid ethoxylated triglycerides, enone triglyceride derivatives, aldehyde triglyceride derivatives, monoglyceride derivatives, diglyceride derivatives and triglyceride derivatives, and salts of medium chain triglycerides. Ester derivatives optionally include alkyl ester derivatives such as methyl, ethyl, propyl, butyl, hexyl, etc. The oil can be spray dried onto a solid support, such as maltodextrin, to facilitate delivery in powder form. At least one medium chain triglyceride is optionally administered at between 5 grams and 50 grams, between 10 grams and 40 grams, or between 15 grams and 30 grams. As non-limiting examples, the medium chain triglyceride is administered at 5 grams, 6 grams, 7 grams, 8 grams, 9 grams, 10 grams, 11 grams, 12 grams, 13 grams, 14 grams, 15 grams, 17 grams, 19 grams, 20 grams, 22 grams, 24 grams, 26 grams, 28 grams, 30 grams, 32 grams, 34 grams, 36 grams, 38 grams, or 40 grams.
[0056] Non-limiting examples of suitable inorganic salts include Na, Mg, V, K, Cr, Mn, Co, Cu, Zn, As, Mo, and / or Se cations in association with appropriate counterions, such as chloride, sulfate, phosphate, or other nutritionally acceptable counterions known in the art.
[0057] In still further embodiments, contemplated compositions may further comprise other nutritional substrates such as free amino acids, amino acid metabolites, vitamins, minerals, electrolytes and metabolic optimizers such as NADH, soluble ubiquinol, tetrahydrobiopterin, alpha-ketoglutaric acid, carnitine and / or alpha lipoic acid, nutritional cofactors, calcium beta-methyl-beta-hydroxybutyrate, arginine alpha-ketoglutarate, sodium R-alpha lipoate, thiamine, riboflavin, niacin, pyridoxine, ascorbic acid, citric acid, malic acid, sodium benzoate, potassium sorbate, acesulfame K, aspartame, xanthan gum or combinations thereof. Non-limiting examples of nutritional cofactors include R-alpha lipoic acid, acetyl-l-carnitine, ketoisocaproate, alpha-ketoglutarate, alpha-hydroxyisocaproate, creatine, branched chain amino acids (leucine, isoleucine, valine), beta-hydroxy-beta methylbutyrate (HMB), B vitamins, vitamin C, soluble ubiquinol, and carnitine.
[0058] In certain embodiments, the composition comprises an encapsulant and a compound at least partially encapsulated by the encapsulant. The encapsulant may comprise cyclodextrin, nanofibers, or a combination thereof. Non-limiting examples of suitable cyclodextrin encapsulants include any cyclic dextrin molecule formed by enzymatic conversion of starch. Certain enzymes, such as various forms of cycloglycosyltransferase (CGTase), can break the helical structure present in starch to form certain cyclodextrin molecules with three-dimensional polyglucose rings, for example, containing 6, 7, or 8 glucose molecules. For example, α-CGTase can convert starch into α-cyclodextrin with 6 glucose units, β-CGTase can convert starch into β-cyclodextrin with 7 glucose units, and γ-CGTase can convert starch into γ-cyclodextrin with 8 glucose units. Cyclodextrins include, but are not limited to, at least one of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and combinations thereof. Cyclodextrins may be derivatized. Suitable derivatized cyclodextrins include, but are not limited to, hydroxyalkylated cyclodextrins, such as 2-hydroxypropyl β-cyclodextrin, 3-hydroxypropyl β-cyclodextrin, 2,3-dihydroxypropyl β-cyclodextrin, and hydroxyethyl β-cyclodextrin, and methylated cyclodextrins, such as methyl β-cyclodextrin. Non-limiting examples of suitable nanofiber encapsulants include any nanofiber web or mat that is a collection of nonwoven randomly oriented or aligned nanofibers, such as those formed from a variety of inorganic, organic, or biopolymers. EXAMPLES
[0059] Step 1 – Esterification of 2-oxoglutaric acid with ethanol. [ka] To a vigorously stirred pre-cooled (close to 0 °C) solution of 2-oxoglutaric acid (30 g, 205.3 mmol) in 300 mL of absolute ethanol (>99%), acetyl chloride (44 mL, 616 mmol, 3 equiv.) was added at a rate sufficient to maintain the desired temperature (0-5 °C, total addition time was 1 h). The reaction was stirred at 0-5 °C for an additional 3.5 h. After that time, only a small amount of unreacted substrate was observed in the reaction mixture (TLC monitoring: hexane / AcOEt = 7:3 v / v). The mixture was then diluted with 300 mL of AcOEt, washed with saturated NaHCO3 (3 × 300 mL), saturated NaCl (150 mL), dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure to give 38.6 g of product of 93% purity containing 3.2% acetal and 3.3% unknown impurity (GC-FID). 1 The 1 H NMR spectrum was consistent with the chemical structure.
[0060] Step 2 – Enzymatic transesterification of diethyl 2-oxoglutarate with (R)-1,3-butanediol (batch mode). [ka] A mixture of diethyl 2-oxoglutarate (10.0 g, 49.5 mmol, 1 equiv., crude intermediate from step 1), (R)-1,3-butanediol (53.5 g, 593 mmol, 12 equiv.) and 2.3 g of Novozym 435 was stirred at 45 °C and 10 mbar. The reaction progress was monitored by TLC (CH2Cl2 / MeOH=9 / 1 v / v) and GF-FID. If the reaction slowed down, additional portions of Novozym 435 were added. In total, 3.35 g of Novozym 435 were added, with a total reaction time of 300 h, followed by filtration of all insoluble material. Excess (R)-1,3-butanediol was bulb-to-bulb distilled from the filtrate (80 °C, 0.05 mbar, distillation time 60 min). The resulting 10.9 g of material contained 78% of the desired diester of 2-oxoglutaric acid and (R)-1,3-butanediol, 15% R-1,3-butanediol and some unknown impurities (GC-FID). 1 The 1 H NMR spectrum corresponded to the chemical structure of the desired compound in the purity obtained.
[0061] Step 2 – Enzymatic transesterification of diethyl 2-oxoglutarate with (R)-1,3-butanediol (flow mode). [ka]
[0062] A mixture of diethyl 2-oxoglutarate (10.0 g, 49.5 mmol, 1 equiv., crude intermediate from step 1), (R)-1,3-butanediol (53.5 g, 593 mmol, 12 equiv.) was passed through a Teflon tube φ=3 mm containing Novozym 435 (0.88 g) for 20 h. The product was collected in a flask and the volatiles were subsequently evaporated under reduced pressure (45 °C, 10 mbar). This procedure was repeated three times until complete conversion of diethyl 2-oxoglutarate was observed by TLC (CH2Cl2 / MeOH=9 / 1 v / v) and GC-FID. The product was collected and all volatiles were evaporated under reduced pressure followed by bulb-to-bulb distillation (80 °C, 0.05 mbar, distillation time 120 min) to give 7.45 g of the final material. The resulting 7.45 g of material contained 87% of the desired diester of 2-oxoglutaric acid and (R)-1,3-butanediol, 7% of R-1,3-butanediol and some unknown impurities (GC-FID). 1 The 1 H NMR spectrum corresponded to the chemical structure of the desired compound in the purity obtained.
[0063] As will be readily appreciated, numerous alternative compounds can be produced using substituted or unsubstituted dicarboxylic acids in place of 2-oxo-glutaric acid following substantially the same protocols as described in the examples above. Suitable exemplary alternative dicarboxylic acids can be found in Tables 1-4 above. Additionally, when the dicarboxylic acid is a substituted dicarboxylic acid containing an amino group, conventional protecting groups (e.g., t-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl, etc.) can be used.
[0064] In some embodiments, numbers expressing quantities of ingredients, properties, such as concentrations, reaction conditions, etc., used to describe and claim certain embodiments of the present invention should be understood to be modified in some cases by the term "about". Thus, in some embodiments, the numerical parameters set forth in this specification and the appended claims are approximations that may vary depending on the desired properties sought to be obtained by a particular embodiment. The recitation of ranges of values herein is merely intended to serve as a shorthand method of individually referring to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated herein as if it were individually recited herein.
[0065] As used herein, the term "administering" a pharmaceutical composition or drug refers to both direct and indirect administration of the pharmaceutical composition or drug, where direct administration of the pharmaceutical composition or drug is typically performed by a medical professional (e.g., a doctor, a nurse, etc.), and indirect administration involves providing or making the pharmaceutical composition or drug available to a medical professional for direct administration (e.g., by injection, infusion, oral delivery, topical delivery, etc.). It should be further noted that the terms "predicting" or "predicting" a condition, susceptibility to development of a disease, or response to an intended treatment is intended to encompass the act of predicting or the prediction (but not treatment or diagnosis) of a condition, susceptibility, and / or response (including rate of progression, improvement, and / or duration of a condition in a subject).
[0066] All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any example or exemplary language (e.g., "such as") provided in connection with a particular embodiment herein is intended only to further clarify the invention and does not impose limitations on the scope of the invention as otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0067] As used in the description herein and throughout the claims which follow, the meanings of "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of "in" includes "in" and "on," unless the context clearly dictates otherwise. Also, as used herein, the term "coupled to" is intended to include both direct coupling (where the two elements coupled to each other touch each other) and indirect coupling (where at least one additional element is between the two elements), unless the context clearly dictates otherwise. Thus, the terms "coupled to" and "coupled with" are used interchangeably.
[0068] It should be apparent to one skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. Accordingly, the subject matter of the present invention should not be limited except as by the scope of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the terms "comprises" and "comprising" should be interpreted to refer to elements, components, or steps in a non-exclusive manner, indicating that the referred element, component, or step may be present, used, or combined with other elements, components, or steps not expressly mentioned. When the specification or claims refer to at least one something selected from the group consisting of A, B, C.... and N, the text should be interpreted as requiring only one element from the group, not A plus N or B plus N, etc.
Claims
1. Formula I 【Chemistry 1】 (wherein X is a linear alkyl group optionally containing at least one double bond and optionally substituted with a substituent selected from the group consisting of methyl, methylene, hydroxyl and keto groups, and * denotes a chiral carbon atom). A nutritionally acceptable carrier in combination with a diester compound having a structure according to and formulated for oral administration.
2. X is (CH 2 ) n 2. The composition of claim 1, wherein n is an integer between 1 and 10.
3. 3. The composition of claim 1 or 2, wherein the linear alkyl group is substituted with at least one keto group.
4. 4. The composition of claim 1, wherein the linear alkyl group is substituted with at least one hydroxyl group.
5. X is (CH 2 ) n 5. The composition of claim 1, wherein when n is an integer greater than 3, the linear alkyl group is substituted with at least one amino group.
6. 6. The composition of claim 1, wherein the linear alkyl group is substituted with at least one methyl group.
7. 7. The composition of claim 1, wherein the linear alkyl group has at least one double bond.
8. 8. The composition of claim 1, wherein at least one of the chiral carbon atoms has an (R)-configuration.
9. 9. The composition according to claim 1, wherein the diester compound is a substrate for a lipase or esterase.
10. 10. The composition of claim 9, wherein the diester compound produces (R)-1,3-butanediol after hydrolysis by a lipase or esterase.
11. 11. The composition of claim 9 or 10, wherein the diester compound generates metabolically relevant dicarboxylic acids after hydrolysis by a lipase or esterase.
12. 12. The composition of claim 11, wherein the metabolically relevant dicarboxylic acid is an intermediate or substrate in the tricarboxylic acid (TCA) cycle, an intermediate or substrate of beta-oxidation, an intermediate or substrate of glycolysis, or an intermediate or substrate of gluconeogenesis.
13. 12. The composition of claim 11, wherein the metabolically relevant dicarboxylic acids are selected from the group consisting of succinic acid, malic acid, fumaric acid and alpha-ketoglutaric acid.
14. The diester compound is represented by formula II, III, IV or V 【Chemistry 2】 【change】 14. The composition of claim 1 having a structure according to
15. 15. The composition of claim 1, further comprising (R)-1,3-butanediol, (R)-3-hydroxybutyrate and / or a dicarboxylic acid.
16. 16. The composition of any one of claims 1 to 15, formulated as a liquid concentrate, a ready-to-drink beverage, or a gel.
17. 16. The composition of any one of claims 1 to 15, formulated as a solid, the solid being selected from the group consisting of a bulk powder, a tablet or capsule, a lozenge, a dissolving film, or a snack bar.
18. 18. The composition of any one of claims 1 to 17, formulated into a solid dosage unit to provide between 20 mg and 1,000 mg of the diester compound per dosage unit to a consumer ingesting a dosage unit of the composition.
19. 19. The composition of any one of claims 1 to 18, formulated into a liquid dosage unit to provide a consumer ingesting a dosage unit of the composition with between 2 g and 30 g of the diester compound per dosage unit.
20. 1. A method for increasing (R)-3-hydroxybutyrate in a mammal, comprising: orally administering to a mammal a nutritional composition according to any one of claims 1 to 19. Including, A method comprising enzymatic conversion of a diester compound in a mammal to produce (R)-1,3-butanediol and a dicarboxylic acid, and enzymatic conversion of (R)-1,3-butanediol in a mammal to produce (R)-3-hydroxybutyrate.
21. 21. The method of claim 20, wherein the composition is administered to the mammal in a solid dosage unit to provide between 20 mg and 1,000 mg of the diester compound.
22. 21. The method of claim 20, wherein the composition is administered in a solid dosage unit to provide the mammal with between 2 g and 30 g of the diester compound.
23. 1. A method for producing a nutritional composition comprising: combining the diester compound with a nutritionally acceptable carrier to thereby produce a nutritional composition, the diester compound being of formula I 【Chemistry 3】 (wherein X is a linear alkyl group optionally containing at least one double bond and optionally substituted with a substituent selected from the group consisting of methyl, methylene, hydroxyl and keto groups, and * denotes a chiral carbon atom). and formulating a nutritional composition for oral administration; A method comprising:
24. 24. The method of claim 23, wherein the diester compound is produced by direct esterification of metabolically relevant dicarboxylic acids and 1,3-butanediol.
25. 25. The method of claim 24, wherein the metabolically relevant dicarboxylic acid is an intermediate or substrate in the tricarboxylic acid (TCA) cycle, an intermediate or substrate of beta-oxidation, an intermediate or substrate of glycolysis, or an intermediate or substrate of gluconeogenesis.
26. 25. The method of claim 24, wherein the metabolically relevant dicarboxylic acids are selected from the group consisting of succinic acid, malic acid, fumaric acid and alpha-ketoglutaric acid.
27. 27. The method of any one of claims 23 to 26, wherein the 1,3-butanediol is (R)-1,3-butanediol.
28. 28. The method of any one of claims 23 to 27, wherein the direct esterification comprises enzymatic esterification.
29. 24. The method of claim 23, wherein the diester compound is produced by transesterification of a dicarboxylic acid diester intermediate and 1,3-butanediol.
30. 30. The method of claim 29, wherein the dicarboxylate diester intermediate is a diester of ethanol and a metabolically relevant dicarboxylic acid, and the metabolically relevant dicarboxylic acid is an intermediate in the tricarboxylic acid (TCA) cycle, an intermediate or substrate of beta-oxidation, an intermediate or substrate of glycolysis, or an intermediate or substrate of gluconeogenesis.
31. 31. The method of claim 30, wherein the metabolically relevant dicarboxylic acids are selected from the group consisting of succinic acid, malic acid, fumaric acid and alpha-ketoglutaric acid.
32. 32. The method of any one of claims 29 to 31, wherein the 1,3-butanediol is (R)-1,3-butanediol.
33. 33. The method of any one of claims 29 to 32, wherein the interesterification comprises enzymatic interesterification.
34. X is (CH 2 ) n 33. The method of any one of claims 23 to 32, wherein n is an integer between 1 and 10.
35. The diester compound is represented by formula II, III, IV or V 【Chemistry 4】 【change】 33. The method of any one of claims 23 to 32, having a structure according to
Citation Information
Patent Citations
Nutrient polyesters
US4701443A
